Geriatrics addresses the health needs of older adults, focusing on frailty, dementia, falls, and chronic disease management.
Send us all your questions or requests, and our expert team will assist you.
The advent of high-resolution imaging technologies has revolutionized the diagnostic pathway for macular degeneration. In the past, diagnosis relied heavily on direct visualization of the fundus using an ophthalmoscope, which offered a limited, two-dimensional view. Today, the evaluation is a sophisticated, multi-modal process that creates a histological-grade map of the living retina. This precision is paramount for regenerative medicine, as the success of future stem cell therapies depends on accurately identifying the damaged retinal layers and those that remain viable. The diagnostic process is not merely about confirming the disease but about defining the phenotype, staging the progression, and identifying the “therapeutic window” where regenerative interventions might be most effective.
The evaluation protocol involves a synthesis of functional testing, which measures what the patient sees, and structural imaging, which measures the physical integrity of the retinal tissue. This dual approach ensures that subtle anatomical changes are correlated with visual performance, enabling early detection of disease activity before irreversible vision loss occurs.
While OCT shows structure, angiography shows circulation. These tests involve injecting a dye into a vein in the arm and photographing the dye as it passes through the blood vessels of the eye.
Fundus Autofluorescence is a critical imaging modality for tracking the progression of dry macular degeneration and assessing the health of the RPE. It does not require dye injection but relies on the natural fluorescence of lipofuscin, the metabolic waste product that accumulates in the RPE.
The role of genetic testing in routine clinical practice is debated, but in the context of research and personalized medicine, it is gaining importance.
The diagnostic evaluation is a dynamic process that evolves as the disease progresses. From the initial identification of high-risk drusen to the precise mapping of geographic atrophy for surgical planning, these tools provide the data necessary to navigate the complex landscape of macular degeneration.
Structural imaging must be complemented by functional assessments that quantify how macular changes affect daily tasks. Liv Hospital incorporates several standardized tests into the diagnosis and evaluation workflow.
The Amsler grid is a simple, bedside tool where patients identify distortions or missing lines in a checkerboard pattern. Positive findings often correlate with early metamorphopsia, prompting immediate imaging.
This test measures the ability to discern subtle differences between shades of gray, a function that deteriorates early in AMD even when visual acuity remains relatively preserved.
Standardized questionnaires such as the National Eye Institute Visual Function Questionnaire (NEI VFQ‑25) capture patient‑reported outcomes, providing a holistic view of how macular degeneration impacts quality of life.
Microperimetry maps retinal sensitivity while simultaneously tracking eye movements, allowing clinicians to pinpoint functional deficits that correspond to structural lesions seen on OCT.
Results from these functional tests are recorded alongside imaging data, enabling a nuanced risk stratification. For example, a patient with minimal drusen but significant contrast sensitivity loss may be monitored more closely than suggested by imaging alone.
The combined structural‑functional approach ensures that treatment decisions are based on both objective disease markers and the patient’s lived experience.
Accurate diagnosis and evaluation requires ruling out retinal disorders that can mimic macular degeneration. Common mimickers include:
Distinguishing features are identified through a combination of history, imaging, and functional testing. For instance, CSC typically shows a focal leakage point on FFA without the extensive drusen pattern of AMD. Myopic changes are evident on axial length measurements, while DME is associated with widespread retinal thickening and microaneurysms.
When uncertainty persists, Liv Hospital’s retina specialists may request additional investigations such as:
By systematically excluding these alternatives, the care team ensures that the final diagnosis truly reflects macular degeneration, preventing misdirected treatments.
Liv Hospital combines JCI accreditation, cutting‑edge ophthalmic technology, and a dedicated international patient program. Our multilingual coordinators handle appointments, transportation, interpreter services, and accommodation, making the diagnostic journey seamless for patients traveling from abroad. With a team of board‑certified retina specialists and access to the latest therapeutic trials, we deliver personalized, evidence‑based care that aligns with global best practices.
Ready to schedule your comprehensive macular evaluation? Contact Liv Hospital today to arrange a personalized appointment and experience world‑class eye care with full support for international patients.
Send us all your questions or requests, and our expert team will assist you.
The diagnostic pathway for AMD starts with a comprehensive clinical assessment that records visual acuity, intra‑ocular pressure, and a slit‑lamp fundus examination. A detailed history captures age, genetics, lifestyle, and systemic conditions. Based on initial findings, clinicians order imaging modalities such as optical coherence tomography to view retinal layers, fluorescein angiography for vascular leakage, indocyanine green angiography for deeper choroidal assessment, and fundus autofluorescence for metabolic changes. Functional tests like the Amsler grid, contrast sensitivity, reading speed questionnaires, and microperimetry are added to gauge the impact on daily activities. All data are integrated to stage the disease and guide treatment.
Optical coherence tomography provides high‑resolution cross‑sectional images of the retina. In dry (atrophic) AMD, OCT visualizes elevated drusen, thinning of the retinal pigment epithelium, and subtle irregularities. In wet (neovascular) AMD, the same scan highlights hyper‑reflective lesions, sub‑retinal or intraretinal fluid, and the presence of choroidal neovascular membranes. Quantitative measurements of retinal thickness and fluid volume allow clinicians to monitor disease activity over time and decide when anti‑VEGF therapy is needed.
Fundus fluorescein angiography involves injecting fluorescein dye and capturing rapid sequential images of the retinal vasculature. It is indicated when clinicians need to confirm the presence, location, and extent of choroidal neovascularization, which characterizes wet AMD. FFA helps differentiate active leakage from scar tissue, guides the timing of intravitreal anti‑VEGF injections, and is the gold standard for documenting disease progression in clinical trials. Although invasive, its diagnostic value outweighs the risks when wet AMD is suspected
Functional testing complements structural imaging by measuring how macular changes affect daily tasks. The Amsler grid detects metamorphopsia by having patients identify distorted lines. Contrast sensitivity testing quantifies the ability to discern subtle gray‑scale differences, often declining before visual acuity drops. Standardized questionnaires such as the NEI VFQ‑25 capture patient‑reported outcomes on reading, driving, and quality of life. Microperimetry maps retinal sensitivity while tracking eye movements, linking functional deficits directly to anatomical lesions seen on OCT. Together, these tests inform risk stratification and rehabilitation planning.
After staging the disease using the AREDS classification, patients with early dry AMD are advised to modify risk factors—quit smoking, control blood pressure, and adopt a diet rich in antioxidants. AREDS2 supplements (vitamins C, E, zinc, copper, lutein, zeaxanthin) may slow progression. For intermediate or advanced dry AMD, monitoring is intensified. Wet AMD requires prompt intravitreal anti‑VEGF therapy (e.g., ranibizumab, aflibercept) to halt neovascular leakage. In cases of extensive scarring or geographic atrophy, low‑vision aids, vision therapy, and counseling become central to maintaining quality of life.
Your Comparison List (you must select at least 2 packages)
